FDA approves Adjuvant Yervoy in melanoma based on results of EORTC trial 18071
Based on the results of EORTC trial 18071, the FDA expanded the approval of Yervoy (ipilimumab) in melanoma to include adjuvant treatment of patients with stage 3 melanoma at high risk of recurrence following complete resection.
Nov 13, 2015
0
4